Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/21/2022* -- Results Q2 2022 -- 1.54 --
07/21/2022* -- Earnings Call Q2 2022 -- -- --
02/02/2022 -- Results Q4 2021 1.40 1.41 -0.97%
02/02/2022 -- Earnings Call Q4 2021 -- -- --
10/26/2021 -- Results Q3 2021 1.71 1.66 3.17%
10/26/2021 -- Earnings Call Q3 2021 -- -- --
07/21/2021 -- Results Q2 2021 1.66 1.49 11.71%
07/21/2021 -- Earnings Call Q2 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/21/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 02/02/2022
Beat/Miss Upgrade
Return Since 8.41%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
URL https://www.novartis.com
Investor Relations URL https://www.novartis.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 21, 2022 (est.)
Last Earnings Release Feb. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 08, 2022

Dividends

Dividend Per Share (TTM) 3.325
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.806
Yield to Sector 1.935
Yield to Industry 1.107
Last Dividend Amt. 3.325
Dividend Frequency Annually
Last Ex-Dividend Date Mar. 08, 2022
Yield (TTM) 3.72%
Forward Yield 3.72%
Payout Ratio 31.04%
Cash Payout Ratio 64.61%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-4.67%
-12.13%
19.40%
5.88%
14.34%
3.41%
-3.82%
6.47%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
17.76%
--
-41.83%
30.30%
-43.37%
48.40%
-48.75%
-62.10%
134.7%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-9.77%
48.34%
-7.54%
-5.54%
-32.86%
37.32%
-0.39%
-15.61%
2.02%
As of May 20, 2022.

Profile

Edit
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
URL https://www.novartis.com
Investor Relations URL https://www.novartis.com/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 21, 2022 (est.)
Last Earnings Release Feb. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 08, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PPH 22.51M USD 5.24%
PID 22.72M USD 2.94%
LGRCX 371.12M USD 2.82%
TEDRX 253.16M USD 2.62%
THW 11.92M USD 2.03%
PIEMX 184.65M USD 1.87%
DOXGX 1.699B USD 1.72%
DFIV 61.66M USD 1.59%
VPMCX 928.13M USD 1.32%
DOXBX 172.10M USD 1.09%
AVDE 13.75M USD 1.01%
DFAI 9.430M USD 0.63%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NVS Tweets